BioStock: Pre-clinical data indicates wider use for Cyxone’s T20K in MS

Biotech company Cyxone is developing T20K, a drug candidate with first-in-class potential for the treatment of multiple sclerosis. Recently, Cyxone’s research partner, the Medical University of Vienna, presented pre-clinical data supporting T20K as a treatment for MS in combination with a kappa opioid receptor agonist, the combination having potential expanded therapeutic utility. BioStock reached out to COO Carl-Magnus Högerkorp for a comment.

Read the interview with Cyxone's COO Carl-Magnus Högerkorp at biostock.se:

https://www.biostock.se/en/2021/11/pre-clinical-data-indicates-wider-use-for-cyxones-t20k-in-ms/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/